Compare McKesson Corporation (MCK) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs S&P Global Inc — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while S&P Global Inc trades at $407.82 (market cap $118.72B). The key difference: McKesson Corporation and S&P Global Inc are close in size by market cap, and S&P Global Inc pays the higher dividend (0.96%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and S&P Global Inc for 123 Days on average.
| MCK | SPGI | |
|---|---|---|
Market Cap | $108.46B | $118.72B |
Volume | 712,607 | 1,647,917 |
Sector | Health | Financials |
52-Week High | $995.69 | $517.92 |
52-Week Low | $725.17 | $370.42 |
Typical Hold Time | 74 Days | 123 Days |
Enterprise Value | $115.00B | $130.21B |
Dividend Yield | 0.4% | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
S&P Global (SPGI) trades at $402.73, up 1.91% with strong analyst support (85.7% buy ratings) and a $509.50 consensus price target. The stock shows solid fundamentals with 30.54% net margins and consistent revenue growth from $14.2B to $15.3B. Recent technical indicators show bearish momentum despite beating earnings expectations in two of the last three quarters. The company continues expanding through strategic acquisitions like OpenZeppelin and new product launches in digital asset risk assessment.
SPGI presents a compelling growth story with expanding margins and strategic positioning in financial data services. Key risks include market sensitivity to economic cycles and integration challenges from recent acquisitions. With strong cash flow generation and a dominant market position, the stock offers upside potential despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
